Solid Biosciences (NASDAQ:SLDB) focuses on developing therapies for Duchenne muscular dystrophy (DMD) and other neuromuscular diseases. With a dedication to improving the lives of patients affected by these conditions, the company's operations span research, development, and advocacy within the neuromuscular disease community. Solid Biosciences is driven by a commitment to advancing scientific research and therapy options for those facing DMD, aiming to address the unmet medical needs of the Duchenne community through innovative solutions and partnerships. Their objectives revolve around progressing their lead gene therapy candidate through clinical trials and ultimately delivering transformative treatments to patients and their families.